Me0328

A549, HeLa, 293T and U2OS cells were cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum (FBS), and 50 U ml⁻¹ penicillin and 50 ng ml⁻¹ streptomycin (Gibco). None of the cell lines used in this study are listed in the database of commonly misidentified cell lines maintained by the International Cell Line Authentication Committee70 (link). The A549 cell line was a gift from the Bradner Lab at Dana-Farber Cancer Institute and was verified by short tandem repeat (STR) profiling. The HeLa and U2OS cells originated from the Jasin Lab at Memorial Sloan Kettering Cancer Center. The 293T cells were gifts from the Alt Lab at Boston Children’s Hospital. Cells were tested for mycoplasma contamination by the IDEXX Laboratories or using the Lonza Mycoplasma kit. Puromycin (Gibco) selection in A549 and 293T cells was at 1.0 μg ml⁻¹. Hygromycin B (Invitrogen) selection in A549 cells was at concentration (200 μg ml⁻¹). Cell synchronization of A549 cells was achieved by growing cells to confluence, reducing FBS to 0.1% for 72 h and releasing cells into DMEM with 20% FBS. A549 cells were treated at the indicated concentrations of pyridostatin (Sigma Aldrich), PhenDC3 (Polysciences), ME0328 (Selleck), KU0058948 (Axon MedChem) or Bleomycin (Santa Cruz Biotechnology) when indicated. All cells were cultured under normal oxygen conditions (21% O₂, 5% CO₂, 37 °C).